NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Forecast, Price & News

$9.82

-0.07 (-0.71%)

(As of 09/21/2023 ET)

Compare

Today's Range: $9.68
▼
$9.99
50-Day Range: $9.85
▼
$12.02
52-Week Range: $7.52
▼
$32.88

Volume: 19,660 shs
Average Volume: 71,919 shs
Market Capitalization: $800.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.67

NewAmsterdam Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 120.6% Upside
$21.67 Price Target
Short Interest: Healthy
0.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -1.18
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.92) to ($1.41) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

449th out of 961 stocks

Pharmaceutical Preparations Industry

200th out of 448 stocks

3.5

Analyst's Opinion

Consensus Rating
NewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.67, NewAmsterdam Pharma has a forecasted upside of 120.6% from its current price of $9.82.
Amount of Analyst Coverage
NewAmsterdam Pharma has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.91% of the float of NewAmsterdam Pharma has been sold short.
Short Interest Ratio / Days to Cover
NewAmsterdam Pharma has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NewAmsterdam Pharma has recently decreased by 0.46%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
NewAmsterdam Pharma does not currently pay a dividend.
Dividend Growth
NewAmsterdam Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NAMS.

0.5

News and Social Media Coverage

News Sentiment
NewAmsterdam Pharma has a news sentiment score of -1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for NewAmsterdam Pharma this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NewAmsterdam Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.50% of the stock of NewAmsterdam Pharma is held by insiders.
Percentage Held by Institutions
96.46% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($1.92) to ($1.41) per share.
Price to Book Value per Share Ratio
NewAmsterdam Pharma has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NAMS Price History

30 days | 90 days | 365 days | Advanced Chart

NAMS Stock News Headlines

September 21, 2023 | finance.yahoo.com

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation

September 20, 2023 | finance.yahoo.com

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

September 21, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 19, 2023 | msn.com

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

August 16, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: NewAmsterdam Pharma Company (NAMS), Legend Biotech (LEGN)

August 10, 2023 | finance.yahoo.com

NewAmsterdam Pharma First Half 2023 Earnings: €0.92 loss per share (vs €1.50 profit in 1H 2022)

August 7, 2023 | finance.yahoo.com

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

August 2, 2023 | finance.yahoo.com

RA Capital Management, L.P. Boosts Position in NewAmsterdam Pharma Co NV

September 21, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 2, 2023 | gurufocus.com

RA Capital Management, L.P. Acquires Stake in NewAmsterdam Pharma Co NV

July 25, 2023 | finance.yahoo.com

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

July 17, 2023 | finance.yahoo.com

Investing in NewAmsterdam Pharma (NASDAQ:NAMS) a year ago would have delivered you a 21% gain

July 4, 2023 | seekingalpha.com

NewAmsterdam Pharma: Exciting Cardiovascular Drug Targeting The Market

June 19, 2023 | seekingalpha.com

NewAmsterdam Pharma: Excellent LDL-C Data But Unknown In The U.S.

June 9, 2023 | finance.yahoo.com

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

June 8, 2023 | finance.yahoo.com

After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)

June 7, 2023 | msn.com

Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday

June 7, 2023 | marketwatch.com

NewAmsterdam Pharma Shares Slide After Secondary Offering >NAMS

June 7, 2023 | msn.com

NewAmsterdam Pharma shares dip on pricing upsized secondary stock offering at $11.50/share

June 7, 2023 | finance.yahoo.com

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

June 6, 2023 | finance.yahoo.com

NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares

June 6, 2023 | finance.yahoo.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) most popular amongst private equity firms who own 58% of the shares, institutions hold 20%

June 5, 2023 | finance.yahoo.com

NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients

June 3, 2023 | finance.yahoo.com

NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

May 31, 2023 | finance.yahoo.com

NewAmsterdam Pharma to Present at Jefferies Healthcare Conference

May 23, 2023 | finance.yahoo.com

NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023

May 8, 2023 | finanznachrichten.de

NewAmsterdam Pharma Company B.V.: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights

See More Headlines

Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

NAMS Company Calendar

Today: 9/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NAMS
CUSIP: N/A
CIK: 1936258
Web: www.newamsterdampharma.com
Phone: 352062971
Fax: N/A
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.67
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $19.00
Forecasted Upside/Downside: +120.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,230,000.00
Net Margins: N/A
Pretax Margin: -80.05%
Return on Equity: -67.45%
Return on Assets: -33.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.15
Quick Ratio: 12.64

Sales & Book Value

Annual Sales: $102.74 million
Price / Sales: 7.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.26 per share
Price / Book: 1.57

Miscellaneous

Outstanding Shares: 81,560,000
Free Float: 79,521,000
Market Cap: $803.37 million
Optionable: Not Optionable
Beta: -0.35

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Michael Harvey Davidson FACC (Age 66)
Facc., Facp., M.D., CEO, Pres, Exec. Board Member & Director

Dr. Johannes Jacob Pieter Kastelein FESC (Age 69)
M.D., Ph.D., Founder, Chief Scientific Officer, Member of Exec. Board & Director

Ms. Louise Kooij (Age 47)
Interim Chief Financial Officer

Mr. Douglas F. Kling (Age 50)
Chief Operating Officer

Mr. Jim Jacobson
Chief Legal Officer & Sec.

Dr. Marc Ditmarsch M.D. (Age 56)
Chief Devel. Officer

Ms. Lina Gugucheva (Age 36)
Chief Bus. Officer

Dr. Sheng Cui Ph.D.
VP & Head of Chemistry Manufacturing and Controls (CMC)

Ms. Annie Neild
VP & Head of Regulatory Affairs

Mr. William Jones Jr. (Age 59)
M.B.A., Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NAMS Stock - Frequently Asked Questions

Should I buy or sell NewAmsterdam Pharma stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NAMS shares.
View NAMS analyst ratings or view top-rated stocks.
What is NewAmsterdam Pharma's stock price forecast for 2023?: 4 analysts have issued 12-month target prices for NewAmsterdam Pharma's stock. Their NAMS share price forecasts range from $19.00 to $24.00. On average, they anticipate the company's share price to reach $21.67 in the next twelve months. This suggests a possible upside of 120.0% from the stock's current price.
View analysts price targets for NAMS or view top-rated stocks among Wall Street analysts.
How have NAMS shares performed in 2023?: NewAmsterdam Pharma's stock was trading at $10.90 on January 1st, 2023. Since then, NAMS stock has decreased by 9.6% and is now trading at $9.85.
View the best growth stocks for 2023 here.
What is NewAmsterdam Pharma's stock symbol?: NewAmsterdam Pharma trades on the NASDAQ under the ticker symbol "NAMS."

Who are NewAmsterdam Pharma's major shareholders?: NewAmsterdam Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (12.84%), RA Capital Management L.P. (11.03%), Medicxi Ventures Management Jersey Ltd (3.52%), Affinity Asset Advisors LLC (0.12%), Monashee Investment Management LLC (0.12%) and Schonfeld Strategic Advisors LLC (0.07%).
How do I buy shares of NewAmsterdam Pharma?: Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NewAmsterdam Pharma's stock price today?: One share of NAMS stock can currently be purchased for approximately $9.85.
How much money does NewAmsterdam Pharma make?: NewAmsterdam Pharma (NASDAQ:NAMS) has a market capitalization of $803.37 million and generates $102.74 million in revenue each year.
How can I contact NewAmsterdam Pharma?: NewAmsterdam Pharma's mailing address is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. The official website for the company is www.newamsterdampharma.com. The company can be reached via phone at 352062971 or via email at max.nowicki@frazierhealthcare.com.

This page (NASDAQ:NAMS) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial